Activation of the Wnt/β-Catenin-IGF2BP1 pathway in cancer cells leads to increased gene expression of a subset of genes, promoting an aggressive tumor phenotype and unfavorable prognostic outcomes. The gene discussed is IGF2BP1; the disease is cancer.